Sankara Eye Hospital, Sathy Road, Sivanandapuram, Coimbatore, Tamil Nadu, India.
Indian J Ophthalmol. 2024 Sep 1;72(9):1304-1307. doi: 10.4103/IJO.IJO_3191_23. Epub 2024 May 20.
To compare the visual outcomes and efficacy of opposite clear corneal incision (OCCI) and toric intraocular lens (IOL) implantation in correcting preexisting astigmatism (PEA) in patients undergoing phacoemulsification.
This prospective interventional comparative study was conducted between June 2022 and January 2023 in patients having cataract with PEA undergoing phacoemulsification. Patients were divided into two groups - group A underwent phacoemulsification with OCCI and group B underwent phacoemulsification with toric IOL implantation. Uncorrected distance visual acuity (UDVA), manifest refractive cylinder, and corneal astigmatism using corneal tomography were measured preoperatively and at 6 weeks postoperatively. The eyes were categorized into three groups with PEA ranging from 1 to 1.5 D, 1.6 to 2 D, and 2.1 to 3 D. Depending upon the white-to-white corneal diameter, the eyes were also categorized into four groups with corneal diameter ranging from 10.5 to 10.9 mm, 11 to 11.4 mm, 11.5 to 11.9 mm, and 12 to 12.4 mm.
Sixty eyes of 60 patients were studied. At postoperative 6 weeks, 83.3% (25 eyes) in the OCCI group and 96.7% (29 eyes) in the toric IOL group achieved UDVA of 6/9 or better. No statistically significant difference was noted between the groups ( P = 0.37). The reduction in mean corneal astigmatism was 0.63 ± 0.37 D in the OCCI group and 0.15 ± 0.12 D in the toric IOL group ( P < 0.001). The residual mean refractive cylinder was 0.60 ± 0.38 D in the OCCI group and 0.05 ± 0.15 D in the toric IOL group at 6 weeks ( P = 0.007).
Both OCCI and toric IOL are effective in correcting PEA. However, in a resource-limited setting, OCCI is a better alternative surgical option for correcting astigmatism of 1-1.5 D during phacoemulsification without requiring additional skills or instruments.
比较行超声乳化白内障吸除术时行对向透明角膜切口(OCCI)联合矫正散光型人工晶状体(IOL)植入术与单纯行超声乳化白内障吸除术治疗白内障合并术前散光(PEA)的临床疗效。
本前瞻性干预性对照研究于 2022 年 6 月至 2023 年 1 月在因白内障合并 PEA 而行超声乳化白内障吸除术的患者中进行。患者分为两组:A 组行超声乳化白内障吸除术联合 OCCI,B 组行超声乳化白内障吸除术联合矫正散光型 IOL 植入术。分别于术前和术后 6 周测量未矫正远视力(UDVA)、角膜散光(采用角膜地形图测量)和角膜散光。根据术前散光程度将患者分为三组:11.5 D、1.62 D 和 2.13 D。根据角膜直径与角膜缘白到白距离的比值(white-to-white corneal diameter,WTWCD)将患者分为四组:WTWCD 值为 10.510.9 mm、1111.4 mm、11.511.9 mm 和 12~12.4 mm。
共纳入 60 例(60 只眼)患者。术后 6 周时,OCCI 组 83.3%(25 只眼)和矫正散光型 IOL 组 96.7%(29 只眼)患者的 UDVA 达到 6/9 或以上。两组间差异无统计学意义( P = 0.37)。OCCI 组和矫正散光型 IOL 组术后平均角膜散光分别降低 0.63 ± 0.37 D 和 0.15 ± 0.12 D( P < 0.001)。OCCI 组和矫正散光型 IOL 组术后 6 周的平均残留等效球镜度分别为 0.60 ± 0.38 D 和 0.05 ± 0.15 D( P = 0.007)。
OCCI 和矫正散光型 IOL 均能有效矫正 PEA。但在资源有限的情况下,OCCI 是一种更好的替代手术方法,可在超声乳化白内障吸除术中矫正 1~1.5 D 的散光,且无需额外的技能或器械。